Log in

Relevant bibliographies by topics / Antifungal drus / Books

To see the other types of publications on this topic, follow the link: Antifungal drus.

Books on the topic 'Antifungal drus'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Antifungal drus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

St, Georgiev Vassil, New York Academy of Sciences., and International Conference on Drug Research in Immunologic and Infectious Diseases (1st : 1987 : Garden City, N.Y.), eds. Antifungal drugs. New York Academy of Sciences, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Krysan, Damian J., and W. Scott Moye-Rowley, eds. Antifungal Drug Resistance. Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3155-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fernandes, Prabhavathi B., ed. New Approaches for Antifungal Drugs. Birkhäuser Boston, 1992. http://dx.doi.org/10.1007/978-1-4899-6729-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

B, Fernandes P., ed. New approaches for antifungal drugs. Birkhäuser, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Manzoor, Nikhat, ed. Advances in Antifungal Drug Development. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-5165-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

1934-, Yamaguchi Hideyo, Kobayashi George S. 1927-, Takahashi Hisashi 1929-, and International Conference on Antifungal Chemotherapy (1st : 1990 : Oiso-machi, Japan), eds. Recent progress in antifungal chemotherapy. Dekker, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

1923-, Jacobs Paul H., and Nall Lexie 1932-, eds. Antifungal drug therapy: A complete guide for the practitioner. M. Dekker, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

J, Ernst Erika, and Rogers P. David, eds. Antifungal agents: Methods and protocols. Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

International, Telesymposium on Recent Trends in the Discovery Development and Evaluation of Antifungal Agents (1987). Recent trends in the discovery, development and evaluation of antifungal agents: Proceedings of an international telesymposium, May 1987. J.R. Prous Science, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hall, Gerri S. Interactions of yeasts, moulds, and antifungal agents: How to detect resistance. Humana Press, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Willard, Rippon John, and Fromtling Robert A. 1953-, eds. Cutaneous antifungal agents: Selected compounds in clinical practice and development. M. Dekker, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

A, Kucers, ed. The use of antibiotics: A clinical review of antibacterial, antifungal, and antiviral drugs. 5th ed. Butterworth-Heinemann, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Grayson, M. Lindsay. Kucers' the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs : Antibiotics. Hodder Arnold, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

D, Sobel Jack, and Wayne State University. School of Medicine., eds. Clinical perspectives: Terconazole, an advance in vulvovaginal candidiasis therapy : proceedings from a symposium, Laguna Niguel, California, October 15-16, 1987. BMI/McGraw-Hill, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Claire, Murphy, Cain William S. 1941-, Hegsted D. Mark 1914, and Conference Nutrition and the Chemical Senses in Aging: Recent Advances and Current Research Needs (1988 : Sarasota, Fla.), eds. Nutrition and the chemical senses in aging: Recent advances and current research needs. New York Academy of Sciences, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Duff, W. Patrick. Antibiotic use in obstetrics and gynecology. W.B. Saunders Co., 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

MacCallum, Donna M. Antifungal agents. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0046.

Full text

Abstract:

Although invasive fungal infections lead to significant morbidity and mortality, there remain limited numbers of antifungal drugs available to treat these infections. This chapter describes and discusses the therapeutic antifungal agent classes currently available clinically to treat invasive fungal infections. These include the polyenes, azoles, echinocandins, and flucytosine (5-fluorocytosine). For each drug class, those currently used clinically are listed and their modes of action described. The effectiveness of drugs against different fungal species is explored and any drawbacks to the us

APA, Harvard, Vancouver, ISO, and other styles

18

Georgiev, Vassil St. Antifungal Drugs. New York Academy of Sciences, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Lewis, Russell E. Principles of antifungal therapy. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0045.

Full text

Abstract:

Survival from many life-threatening invasive fungal diseases requires the timely administration of an effective systemic antifungal agent at the correct dose. Although some new antifungal agents have been introduced into clinical practice over the last two decades, each of these antifungals has limitations regarding spectrum, pharmacokinetic/pharmacodynamic properties, toxicity, and cost. Therefore, the selection and dosing of antifungal therapy need to be highly individualized. A growing body of evidence suggests that antifungal therapy is often underdosed, especially in critically ill patien

APA, Harvard, Vancouver, ISO, and other styles

20

Ashbee, H. Ruth. Antifungal therapeutic drug monitoring. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0048.

Full text

Abstract:

Therapeutic drug monitoring (TDM), the process of measuring drug concentrations in patients at specified time intervals, aims to ensure that the drug concentrations remain within the efficacious and non-toxic range for that drug. This chapter reviews the rationale for the use of TDM in antifungal therapy, specifically for flucytosine and azoles, including fluconazole, itraconazole, voriconazole, and posaconazole. For each antifungal drug, the bioavailability and excretion of the drug are detailed, as well as specific factors affecting antifungal drug concentrations in patients. The chapter dis

APA, Harvard, Vancouver, ISO, and other styles

21

Antifungal and Antiparasitic Drug Delivery. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03936-307-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Co, Business Communications. The Market for Antifungal Drugs. Business Communications Company, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Prabhavathi, B. F. New Approaches for Antifungal Drugs. Birkhäuser Boston, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

FERNANDES and PRABHAVATHI. New Approaches for Antifungal Drugs. Birkhauser Verlag, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

FERNANDES and PRABHAVATHI. New Approaches for Antifungal Drugs. Birkhauser, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ghannoum, Mahmoud A., John R. Perfect, and Mahmoud Ghannoum. Antifungal Therapy. Taylor & Francis Group, 2017.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ernst, Erika J. Antifungal Agents. Humana Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kim, Jong Heon, Luisa W. Cheng, and Kirkwood Land, eds. Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing. MDPI, 2022. http://dx.doi.org/10.3390/books978-3-0365-4767-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Krysan, Damian J., and W. Scott Moye-Rowley. Antifungal Drug Resistance: Methods and Protocols. Springer, 2023.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Antifungal drugs: (1,3) [beta]-glucan synthase inhibitors. Springer, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

Shen, Howard. MemoCharts Pharmacology: Antifungal drugs (Review chart) (Paperback). Minireview, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Seneviratne, Chaminda Jayampath, and Edvaldo Antonio Ribeiro Rosa, eds. Antifungal Drug Discovery: New Theories and New Therapies. Frontiers Media SA, 2016. http://dx.doi.org/10.3389/978-2-88919-950-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Advances in Topical Antifungal Therapy. Springer, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

Johnson, Elizabeth M. Antifungal susceptibility testing and resistance. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0047.

Full text

Abstract:

The availability of choice of systemically active antifungal agents and the proliferation in the number of fungal species implicated in invasive disease have meant that clinicians are increasingly looking for guidance from clinical laboratory results to help select the most appropriate agent. There are now well-established and predictable patterns of innate in vitro resistance to one or more antifungal agents associated with many yeast and mould species. This chapter provides definitions for the most frequently used terminology and outlines some of the issues surrounding antifungal susceptibil

APA, Harvard, Vancouver, ISO, and other styles

35

Jucker, Ernst. Antifungal Agents: Advances and Problems (Progress in Drug Research). Birkhäuser Basel, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

36

Ernst, Erika J. Antifungal Agents (Methods in Molecular Medicine). Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Recent Trends in the discovery, development and evaluation of antifungal agents. J.R. Prous Science Publishers, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

38

Zirngibl, Ludwig. Antifungal Azoles: A Comprehensive Survey of Their Structures and Properties. Wiley & Sons, Incorporated, John, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

39

Zirngibl, Ludwig. Antifungal Azoles: A Comprehensive Survey of Their Structures and Properties. Wiley-VCH Verlag GmbH, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

40

Warnock, David W. Introduction to medical mycology. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0001.

Full text

Abstract:

The pattern of fungal diseases has changed with the emergence of new pathogens and the resurgence of old ones. Many factors have contributed to this, including medical progress, environmental changes, and the development of drug resistance. The impact of these diseases on human health is not widely recognized, largely because of the many gaps in epidemiological surveillance data. Access to affordable diagnostics and antifungal drugs are critical issues in the developing world. New approaches to prevention and control will be needed if we are to reduce the substantial global burden of ill healt

APA, Harvard, Vancouver, ISO, and other styles

41

Hall, Gerri S. Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance. Humana, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

42

Hall, Gerri S. Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

43

Antifungal Drugs (Annals of the New York Academy of Sciences Vol 544). New York Academy of Sciences, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

44

Dixon, Chrystal. Itraconazole: An Active Antifungal Drug Used in Treating Infection of the Esophagus. Independently Published, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

45

Abu-Elteen, Khalid Hussein Ahmad. Effect of sub-inhibitory concentrations of antifungal drugs on adherence of Candida species. 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kucers, A., S. M. Crowe, M. L. Grayson, and J. F. Hoy. The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 5th ed. A Hodder Arnold Publication, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

47

Combating Fungal Infections Problems And Remedy. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

48

Harrison, Mark. Infections. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198765875.003.0042.

Full text

Abstract:

This chapter describes the pharmacology of infections as they apply to Emergency Medicine, and in particular the Primary FRCEM examination. The chapter lists notifiable diseases and outlines the key details of antibacterial drugs, penicillins, cephalosporins tetracyclines, aminoglycosides, macrolides, the management of tuberculosis, quinolones, urinary tract infections, antifungal preparations, herpes virus infections, and antimalarials. This chapter is laid out exactly following the RCEM syllabus, to allow easy reference and consolidation of learning.

APA, Harvard, Vancouver, ISO, and other styles

49

Hube, Bernhard, and Oliver Kurzai. Candida species. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0011.

Full text

Abstract:

Most pathogenic Candida species are members of the microbiota, but also cause superficial or invasive infections. C. albicans is predominant, followed by C. glabrata, C. parapsilosis, and C. tropicalis. C. albicans is polymorphic and grows as yeast, pseudohyphae, or hyphae. The cell wall has multiple functions in pathogenesis. Metabolism and nutrient up-take strategies facilitate growth in multiple niches within the host. Drug resistance is an intrinsic property of C. glabrata and C. krusei, but can be developed by C. albicans and other Candida species during antifungal therapy. Pathogenicity

APA, Harvard, Vancouver, ISO, and other styles

50

John, Mills, James McCarthy, Suzanne Crowe, Lindsay M. Grayson, and Alvis Kucers. Kucers' the Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. Taylor & Francis Group, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!